What regimens eradicate Heliobacter pylori? by Malaty, Wail & Stigleman, Sue
OCTOBER 2003 / VOL 52, NO 10 · The Journal of Family Practice 799
F R O M T H E F A M I L Y P R A C T I C E I N Q U I R I E S N E T W O R K
Clinical  Inquiries
What regimens eradicate
Heliobacter pylori?
■ EVIDENCE-BASED ANSWER
Fourteen-day triple therapy with a proton pump
inhibitor (PPI) plus clarithromycin and either
amoxicillin or metronidazole is superior to 7-day
therapy in eradicating Heliobacter pylori
(strength of recommendation [SOR]: A, high-
quality meta-analysis). 
Seven-day triple therapy with a PPI or raniti-
dine bismuth citrate plus clarithromycin and
either amoxicillin or metronidazole is also effec-
tive (SOR: A, high-quality systematic review). 
Three-day quadruple therapy with a combina-
tion of PPI, clarithromycin, bismuth subcitrate,
and metronidazole or a combination of PPI, 
clarithromycin, amoxicillin, and metronidazole
also appears to be effective (SOR: B, unblinded
randomized controlled trial).
■ EVIDENCE SUMMARY
The ideal H pylori eradication regimen should
reach an intention-to-treat cure rate of 80%
(Table).1 Effective regimens are:
Fourteen-day triple therapy of PPI + clar-
ithromycin + metronidazole or amoxicillin. A
meta-analysis of 13 studies found the eradica-
tion rate for 14-day therapy was 81% (95% 
confidence interval [CI], 77%–85%), compared
with 72% (95% CI, 68%–76%) for 7-day thera-
py. The eradication rate for 10-day therapy
(83%; 95% CI, 75%–89%), however, was not
significantly better than that for 7-day therapy
(80%; 95% CI, 71%–86%).2 Side effects were
more frequent in the longer therapies, but did
not lead to discontinuation of therapy. 
Seven-day triple therapy of PPI + clar-
ithromycin + metronidazole or amoxicillin. A
high-quality systematic review of 82 studies
using 7-day triple therapy found clarithromycin
500 twice daily yielded a higher eradication rate
than clarithromycin 250 mg twice daily when
combined with a PPI and amoxicillin (87% vs
81%; P<.0001). When clarithromycin was 
combined with a PPI and metronidazole, the
higher dose of clarithromycin did not yield 
significantly higher eradication rates (88% vs
89%, P=.259).3
Seven-day triple therapy of ranitidine bis-
muth citrate + clarithromycin + metronidazole
or amoxicillin. For these therapies, a high-
quality systematic review of 8 studies reported
eradication rates of 81% (95% CI, 77%–84%)
with amoxicillin and 88% (95% CI, 85%–90%)
with metronidazole.4,5 Side effects were not
reported in a uniform manner for the 7-day ther-
apies, but were noted to be mild and did not lead
to significant discontinuation of therapy. Pooled
dropout rates were similar among all regimens.4
What is a Clinical Inquiry?
Clinical Inquiries answer real questions that family
physicians submit to the Family Practice Inquiries
Network (FPIN), a national, not-for-profit consortium
of family practice departments, residency programs,
academic health sciences libraries, primary care
practice-based research networks, and individuals
with particular expertise.
Questions chosen for Clinical Inquiries are those
considered most important, according to results of
web-based voting by family physicians across the U.S.
Answers are developed by a specific method:
• First, extensive literature searches are con-
ducted by medical librarians.
• Clinicians then review the evidence and write
the answers, which are then peer reviewed.
• Finally, a practicing family physician writes a
commentary.
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Three-day quadruple therapy of PPI + 
bismuth + clarithromycin + metronidazole or
PPI+ clarithromycin + amoxicillin + metron-
idazole. An otherwise high-quality but unblind-
ed randomized clinical trial of 234 patients
demonstrated that 2 days of pretreatment with
lansoprazole followed by 3 days of lansoprazole
with clarithromycin, amoxicillin, and metronida-
zole yielded eradication rates comparable with
5-day treatment (81% vs. 89%; P<.05).6
Another randomized clinical trial of 118
patients, blinded to investigators but not
patients, showed that quadruple 3-day therapy
with lansoprazole + bismuth + clarithromycin
+ metronidazole was as effective as 7 days of 
lansoprazole + clarithromycin + metronidazole
(87% vs 86%; P=.94), and had significantly
shorter duration of side effects (2.6 vs 
6.2 days; P<.001). Eradication rates were 
similar in isolates that were resistant or 
sensitive to either metronidazole or 
clarithromycin.7
The problems of emerging clarithromycin
and metronidazole resistance have not been
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Effective therapies for Heliobacter pylori eradication
Regimen Dosage Duration (days) Cost ($)b SOR
PPIa 14 210 A
Clarithromycin 500 mg twice daily
Metronidazole 500 mg twice daily or
amoxicillin 1000 mg twice daily
PPI 7 105 A
Clarithromycin 500 mg twice daily
Amoxicillin 1000 mg twice daily
PPI 7 105 A
Clarithromycin 500 mg twice daily
Metronidazole 500 mg twice daily
Ranitidine bismuth citrate 400 mg twice daily 7 85 A
Clarithromycin 500 mg twice daily
Amoxicillin 1000 mg twice daily
Ranitidine bismuth citrate 400 mg twice daily 7 82 A
Clarithromycin 250 mg twice daily
Metronidazole 500 mg twice daily
PPI 3 46 B
Clarithromycin 500 mg twice daily
Metronidazole 400 mg twice daily
Bismuth subcitrate 240 mg twice daily
PPI (5 days) 3 60 B
Clarithromycin 250 mg twice daily
Amoxicillin 1000 mg twice daily
Metronidazole 400 mg twice daily
a. PPI: standard twice-daily dosing—eg, lansoprazole 30 mg or omeprazole 20 mg 
b. Approximate cost of entire course of therapy from www.drugstore.com, August 2003.
PPI, proton pump inhibitor; SOR, strength of recommendation (for an explanation of evidence ratings, see page 779)
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extensively studied. In 1 review, metronida-
zole-containing regimens eradicated metron-
idazole-sensitive strains more effectively than
metronidazole-resistant strains (weighted dif-
ference, 15%; 95% CI, 8%–20%).4 When an
infection is resistant to metronidazole, amoxi-
cillin should be used instead.4 In areas of high
clarithromycin and metronidazole resistance, a
quadruple regimen might be more effective.7
■ RECOMMENDATIONS FROM OTHERS
The Maastricht Consensus of the European
Heliobacter Study Group1 recommends a 7-day
triple regimen of PPI + clarithromycin + either
metronidazole or amoxicillin or (if clarithromycin
resistance is prevalent) PPI + amoxicillin 500 mg
3 times daily + metronidazole 500 mg 3 
times daily. 
The American College of Gastroenterology 
recommends 14-day therapy of one of the follow-
ing options:8
• PPI + clarithromycin + (metronidazole or amox-
icillin), or ranitidine bismuth citrate + clar-
ithromycin + (metronidazole or amoxicillin).
Tetracycline 500 mg twice a day can be substitut-
ed for amoxicillin or metronidazole
• PPI + bismuth subsalicylate 525 mg + metron-
idazole 500 mg 3 times daily + tetra-cycline 500
mg 4 times daily
• Bismuth subsalicylate 525 mg 4 times daily +
metronidazole 250 mg 4 times daily + tetra-
cycline 500 mg 4 times daily + H2 receptor antag-
onist in standard acid-suppression dose (eg, famo-
tidine 20 mg twice a day for 4 weeks).
The Institute for Clinical Systems Improve-
ment recommends as first-choice treatment a 
7-day PPI/clarithromycin/amoxicillin combina-
tion, and as second choice a 7-day regimen of
PPI, tetracycline 250 mg 4 times daily, metron-
idazole 500 mg twice daily, and bismuth subsal-
icylate 525 mg 4 times daily.9
Wail Malaty, MD, Mountain Area Health Education
Center Rural Track Family Practice Residency,
Hendersonville, NC; Sue Stigleman, MLS, Health
Science Library, Mountain Area Health Education Center,
Asheville, NC
■ CLINICAL COMMENTARY
Patients beginning complex regimens
require counseling
The most effective regimens (>80% eradica-
tion) for H pylori include a 10- to 14-day course
of at least 2 antibiotics and an antisecretory
agent. However, even optimal treatment regi-
mens can fail in approximately 10% of
patients. Poor compliance is among the most
common reasons for treatment failure.
Medication side effects can affect up to 50% of
patients taking triple-agent regimens. 
Treatment regimens with multiple medica-
tions administered several times daily can be
difficult to follow. Convenient packaging con-
taining all daily medications are available to
optimize adherence.
Counseling points for patients should
include how to take the medicine correctly,
expected side effects, the importance of 
completing the entire therapy regimen, and
warnings of specific interactions (eg, alcohol
and metronidazole). Lastly, the patient should
be made aware of the cost of the entire regimen,
which ranges from $50 to $250. 
Laura B. Hansen, PharmD, BCPS, University of
Colorado Health Sciences Center, Denver, Colorado
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Does a knee brace decrease
recurrent ACL injuries?
■ EVIDENCE-BASED ANSWER
After surgical anterior cruciate ligament
(ACL) reconstruction, knee bracing does not
significantly protect against injury during
recovery or afterwards (strength of recom-
mendation [SOR]: C, based on expert opinion).
In addition, the use of a knee brace following
ACL reconstruction does not improve stability
or hasten rehabilitation, either immediately or
for up to 2 years (SOR: A, based on random-
ized controlled trials with heterogenous
results). 
Patients wearing a knee brace after ACL
reconstruction may report subjective enhanced
performance, but measured performance is 
better without the brace (SOR: B, based on an
individual case-control study). 
We found no information specifically about
functional bracing following ACL injuries that
have been managed conservatively. 
■ EVIDENCE SUMMARY
Functional braces are designed to provide stabili-
ty for the unstable knee, but few trials report 
re-injury rates as an outcome. Cadaver studies
show that braces limit tibial rotation and antero-
posterior translation. However, the mechanical
effects of knee bracing in vivo are controversial. 
A study involving 5 patients with chronic
unstable ACL injuries showed some limitation of
movement with functional bracing, but it was
accompanied by slowed muscle performance and
used only low-stress forces.1 Objective findings
during physiologic stress loads are inconclusive.2
Three recent randomized controlled trials 
compared functional bracing with no bracing in
rehabilitation after ACL reconstruction. In a
prospective study of 62 patients, researchers
found no benefit from using a postoperative knee
brace at any stage (2 and 6 weeks; 3, 6, and 24
months) after surgery. Moreover, the brace did not
contribute to a more stable knee during rehabili-
tation or 2-year follow-up.3
A similar study of 50 patients demonstrated no
significant difference in function or laxity at 
2 years.4 A 2-year study comparing 30 braced with
30 nonbraced patients showed improved functional
stability (P<.05) but increased thigh muscle atro-
phy (P<.0001) at 3-month follow-up in the braced
group. However, no significant differences were
seen at other follow-up intervals up to 2 years.5
One study evaluated running, jumping, and
turning performance with and without a function-
al brace in 31 patients who had had an ACL 
reconstruction 5 to 26 months previously. They
measured significantly better performance with-
out bracing; however, more than half the group
perceived enhanced performance with the brace.6
■ RECOMMENDATIONS FROM OTHERS
The American Association of Orthopaedic
Surgeons believes that rehabilitative and func-
tional knee braces can be effective in many
treatment programs. Rehabilitative braces are
more effective in protecting against excessive
flexion and extension than against anterior and
C O N T I N U E D
Patients wearing a knee brace feel
they perform better, but measured
performance improves without one
